Table 3.
Association between severe OD occurrence and/or mortality and treatment status: multivariate analysis
| Factor | Severe OD Relative Risk (95% CI) |
Mortality Relative Risk (95% CI) |
Severe OD or Mortality Relative Risk (95% CI) |
|---|---|---|---|
| CD4 stratum | |||
| ≤ 50/μl | 5.37 (3.87–7.43) | 5.33 (3.82–7.44) | 5.34 (4.10–6.96) |
| 51–200/μl | 2.42 (1.81–3.24) | 3.11 (2.34–4.14) | 2.68 (2.12–3.37) |
| >200/μl | 1.00 | 1.00 | 1.00 |
| WHO stage | |||
| 1,2 | 0.86 (0.61–1.21) | 0.64 (0.45–0.90) | 0.77 (0.58–1.02) |
| 3 | 0.96 (0.72–1.28) | 0.83 (0.62–1.10) | 0.91 (0.72–1.15) |
| 4 | 1.00 | 1.00 | 1.00 |
| Period of treatment | |||
| HAART + Cotrimoxazole | |||
| HAART >6 months | 0.72 (0.49–1.26) | 0.09 (0.04–0.19) | 0.40 (0.30–0.55) |
| HAART 0–6 months | 0.79 (0.53–0.98) | 0.22 (0.12–0.43) | 0.50 (0.35–0.73) |
| Cotrimoxazole alone | 1.00 | 1.00 | 1.00 |
OD: Opportunistic disease; HAART: Highly active antiretroviral therapy
CD4 counts in this analysis are current CD4 counts estimated as described in the Methods section. For each factor (CD4 stratum, WHO stage, Period of treatment), the risk ratios are adjusted for the other two factors as well as age and gender.